Nurix Therapeutics (NRIX) Cash from Investing Activities (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Cash from Investing Activities data on file, last reported at -$123.8 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$123.8 million, down 584.96% year-over-year; the trailing twelve-month figure through Feb 2026 was -$1.5 million (up 99.44% YoY), and the FY2025 annual result was $147.9 million, up 157.37% from the prior year.
• Cash from Investing Activities fell to -$123.8 million in Q1 2026 per NRIX's latest filing, from $346000.0 in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $71.5 million in Q2 2025 and troughed at -$140.8 million in Q4 2024.
• A 5-year average of -$8.1 million and a median of $16.1 million in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities jumped 1777.04% in 2022, then slumped 879.73% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at $55.0 million in 2022, then plunged by 126.13% to -$14.4 million in 2023, then tumbled by 879.73% to -$140.8 million in 2024, then jumped by 100.25% to $346000.0 in 2025, then sank by 35887.86% to -$123.8 million in 2026.
• Business Quant data shows NRIX's Cash from Investing Activities at -$123.8 million in Q1 2026, $346000.0 in Q4 2025, and $50.5 million in Q3 2025.